While there is ongoing research to develop better tools like biochemical markers to differentiate fibrosis stage in MASH patients, the only standard currently used in MASH clinical studies involves ...

The Indian Institute of Technology (IIT) Guwahati and the Bose Institute Kolkata research team have developed an advanced injectable hydrogel designed to release anti-cancer therapies to tumour areas ...

China NMPA has granted acceptance and priority review for the NDA for HUTCHMED’s ORPATHYS (savolitinib) and TAGRISSO (osimertinib) combination ...

SIGA Technologies has gained the Japanese regulatory approval for TEPOXX (tecovirimat) for the treatment of smallpox, mpox and cowpox.

There are now more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

HUTCHMED (China) has entered into agreements to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals (SHPL) ...

The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that ...

Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.

MSD has received the UK MHRA approval for sotatercept, marketed as Winrevair, to treat PAH in the adult population.

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.